Skip to main content

Table 3 Relationships between clinical features of patients and single SNPs

From: Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s disease

Characteristics Total rs4633 C > T rs4680 G > A rs6269 A > G rs4818 C > G
CC CT TT P GG GA AA P AA AG GG P CC CG GG P
n 143 78 56 9   79 56 8   62 67 14   64 66 13  
H&Y stageb 2.0 ± 1.0 2.0 ± 1.5 2.0 ± 1.0 3.0 ± 0.5 0.007** 2.0 ± 1.5 2.0 ± 1.0 2.8 ± 0.5 0.01* 2.5 ± 1.0 2.0 ± 1.0 2.0 ± 0.8 0.07 2.5 ± 1.0 2.0 ± 1.0 2.0 ± 0.8 0.09
Age onset (years)a 59.2 ± 9.2 60.7 ± 9.2 57.5 ± 9.4 57.3 ± 5.6 0.01* 60.7 ± 9.2 57.6 ± 9.4 56.8 ± 5.7 0.01* 59. 5 ± 9.5 58.828.6 60.3 ± 10.6 0.80 59.6 ± 9. 5 58.6 ± 8.6 60.8 ± 10.9 0.89
Disease duration (years)b 6.0 ± 5.0 6.0 ± 4.0 6.0 ± 5.8 9.0 ± 7.5 0.005** 6.0 ± 4.0 6.0 ± 6.0 8.5 ± 9.5 0.005** 6.0 ± 5.3 6.0 ± 5.0 7.5 ± 7.3 0.73 6.0 ± 5.0 6.0 ± 5.0 8.0 ± 8.5 0.75
LED (mg)a 448.8 ± 327.4 386.2 ± 287.5 496.8 ± 358.0 693.2 ± 322.6 0.005** 389.5 ± 287.2 497.7 ± 358.5 692.4 ± 344.8 0.007** 475.3 ± 399.2 425.0 ± 241.7 445.5 ± 346.5 0.56 469.7 ± 396.5 435.0 ± 243.6 416.4 ± 342.2 0.59
Wearing-off (yes, %) 43 (30.1) 18 (23.1) 19 (33.9) 6 (66. 7) 0.008** 18 (22. 8) 20 (35.7) 5 (65.1) 0.009** 20 (32.3) 17 (25.4) 6 (42.9) 0.94 20 (31.3) 18 (27.3) 5 (38.5) 0.87
Dyskinesia (yes, %)b 18 (12.6) 7 (9.0) 9 (16.1) 2 (22.2) 0.12 7 (8.9) 9 (16.1) 2 (25.0) 0.09 8 (12.9) 7 (10. 5) 3 (21.4) 0.76 8 (12.5) 7 (10.6) 3 (23.1) 0.67
UPDRS Part I score b 2.0 ± 3.0 2.0 ± 3.0 3.0 ± 3.0 2.0 ± 3.0 0.92 2.0 ± 3.0 3.0 ± 3.0 2.0 ± 3.5 0.91 2.0 ± 3.0 2.0 ± 3.0 3.0 ± 3.0 0.41 2.0 ± 4.0 2.0 ± 3.0 3.0 ± 3.0 0.31
UPDRS Part II score b 8.0 ± 7.0 8.5 ± 9.0 8.0 ± 7.3 13.0 ± 10.0 0.002** 8.0 ± 9.0 8.0 ± 6.8 13.0 ± 7.8 0.02* 8.0 ± 7.0 8.0 ± 8.0 11.0 ± 7.3 0.48 8.0 ± 7.0 9.0 ± 7.0 9.0 ± 7.5 0.70
UPDRS Part III score a 24.7 ± 12.1 25.9 ± 11.9 21.8 ± 11.6 32. 8 ± 12.3 0.01* 25.8 ± 11.9 22.4 ± 12.1 31.0011.9 0.06 25.3 ± 12.3 24.2 ± 12.1 24.6 ± 11.6 0.82 24.8 ± 12.3 24.4 ± 12.3 26.2 ± 10.3 0.96
UPDRS Part IV score b 3.0 ± 2.0 3.0 ± 2.0 2.0 ± 3.0 5.0 ± 3.0 0.10 3.0 ± 2.0 2.0 ± 3.8 4.5 ± 4.0 0.13 3.0 ± 4.0 2.0 ± 3.0 3.0 ± 2.0 0.98 3.0 ± 4.0 2.5 ± 3.0 3.0 ± 2.0 0.96
UPDRS total scorea 40.0 ± 17.7 41.0 ± 17.4 36.3 ± 16.5 54.8 ± 20.2 0.006** 40.8 ± 17.3 37.1 ± 17.3 52.0 ± 19.7 0.04* 40.7 ± 18.4 38.8 ± 17.4 42.6 ± 15.8 0.79 40.2 ± 18.8 39.0 ± 17.1 44.1 ± 15.5 0.81
NMS scoreb 6.0 ± 6.0 6.0 ± 6.0 6.0 ± 4.8 7.0 ± 9.5 0.60 6.0 ± 6.0 6.5 ± 4.8 6.5 ± 10.8 0.68 7.0 ± 6.3 6.0 ± 6.0 6.5 ± 5.5 0.57 7.0 ± 7.8 6.0 ± 5.3 6.0 ± 6.0 0.38
HAMA scoreb 4.0 ± 6.0 4.0 ± 6.0 5.0 ± 4.5 4.0 ± 14.0 0.48 4.0 ± 6.0 5.0 ± 4.8 4.5 ± 13.3 0.40 5.0 ± 6.0 4.0 ± 4.0 6.0 ± 7.0 0.85 5.0 ± 6.0 4.0 ± 4.0 6.0 ± 6.0 0.93
HAMD scoreb 3.0 ± 4.0 2.0 ± 5.0 4.0 ± 4.0 4.0 ± 6.0 0.40 2.0 ± 5.0 4.0 ± 4.0 3.0 ± 6.5 0.20 2.0 ± 6.3 3.0 ± 4.0 2.0 ± 3.8 0.14 2.0 ± 7.0 3.0 ± 4.0 2.0 ± 2.0 0.41
MMSE scoreb 28.0 ± 3.0 28.0 ± 3.0 28.0 ± 3.0 27.0 ± 4.0 0.49 28.0 ± 3.0 28.0 ± 3.0 27.5 ± 3.0 0.54 28.0 ± 3.0 28.0 ± 3.0 28.0 ± 3.5 0.12 28.0 ± 3.0 28.0 ± 3.0 28.0 ± 3.5 0.13
  1. Data were analyzed with analysis of variance of factorial design with age and sex as covariates
  2. Binary logistic regression model was used to analyze the relation between SNP and motor complication (wearing-off phenomenon and dyskinesia), with age and sex as covariates
  3. *P < 0.05 **P < 0.01
  4. aValues are expressed as the mean ± SD
  5. bValues are expressed as the median ± IQ